Harvard Bioscience, Inc.

NasdaqGM:HBIO 株式レポート

時価総額:US$125.9m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Harvard Bioscience マネジメント

マネジメント 基準チェック /14

Harvard Bioscience'sの CEO はJim Greenで、 Jul2019年に任命され、 の在任期間は 4.92年です。 の年間総報酬は$ 2.39Mで、 24.5%給与と75.5%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の4.4%を直接所有しており、その価値は$ 5.57M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と6.7年です。

主要情報

Jim Green

最高経営責任者

US$2.4m

報酬総額

CEO給与比率24.5%
CEO在任期間4.9yrs
CEOの所有権4.4%
経営陣の平均在職期間1.8yrs
取締役会の平均在任期間6.7yrs

経営陣の近況

Recent updates

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28
When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Dec 11
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?

Nov 26
At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?

Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

CEO報酬分析

Harvard Bioscience の収益と比較して、Jim Green の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$2mUS$586k

-US$3m

Sep 30 2023n/an/a

-US$3m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$574k

-US$10m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$3mUS$574k

-US$288k

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$3mUS$574k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$3mUS$265k

-US$5m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

US$432k

Mar 31 2019n/an/a

-US$819k

Dec 31 2018US$153kn/a

-US$4m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$129kn/a

-US$2m

報酬と市場: Jimの 総報酬 ($USD 2.39M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Jimの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Jim Green (66 yo)

4.9yrs

在職期間

US$2,392,240

報酬

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
James Green
President4.9yrsUS$2.39m4.4%
$ 5.5m
Jennifer Cote
CFO & Treasurer1.4yrsUS$571.27k0.097%
$ 122.1k
David Balcom
Senior Vice President of Operations1.9yrsデータなしデータなし
John Fry
Chief Legal Counsel & Corporation Secretary1.8yrsデータなしデータなし
Ryan Wallace
Senior Vice President of Global Sales1.1yrsデータなしデータなし
Lori Packer
Vice President of Global People Operationsno dataデータなしデータなし
David Sirois
Director of Corporate Accounting & SEC Reportingno dataデータなしデータなし

1.8yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: HBIOの経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
James Green
President9.2yrsUS$2.39m4.4%
$ 5.5m
Alan Edrick
Independent Director4.8yrsUS$213.09k0.53%
$ 661.3k
Bertrand Loy
Lead Independent Director9.6yrsUS$223.06k1.15%
$ 1.4m
Thomas Loewald
Independent Director6.7yrsUS$205.45k0.57%
$ 723.4k
Katherine Eade
Independent Director6.7yrsUS$198.09k0.61%
$ 769.2k

6.7yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: HBIOの 取締役会経験豊富 であると考えられます ( 6.7年の平均在任期間)。